First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma.
Strauss J, Deville JL, Sznol M, Ravaud A, Maruzzo M, Pachynski RK, Gourdin TS, Maio M, Dirix L, Schlom J, Donahue RN, Tsai YT, Wang X, Vugmeyster Y, Beier F, Seebeck J, Schroeder A, Chennoufi S, Gulley JL.
Strauss J, et al. Among authors: gulley jl.
J Immunother Cancer. 2023 May;11(5):e005813. doi: 10.1136/jitc-2022-005813.
J Immunother Cancer. 2023.
PMID: 37236636
Free PMC article.
Clinical Trial.